Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Not yet recruiting 5Recruiting 4Active not recruiting 2

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Rectal Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1

Interventions

Specimen Handling 57Magnetic Resonance Spectroscopy 39Carboplatin 32Cyclophosphamide 29Gemcitabine 28Bevacizumab 24pembrolizumab 23Cisplatin 23Biopsy 23Paclitaxel 22Standard of Care 21Radiotherapy 21Drug Therapy 21fludarabine 20Injections 20Capecitabine 20venetoclax 19Oxaliplatin 19Nivolumab 18Interviews as Topic 17toripalimab 16Dexamethasone 16Blood Specimen Collection 16Radiosurgery 14tislelizumab 13cemiplimab 13anlotinib 13Azacitidine 13Pemetrexed 12Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × disitamab vedotin × 90 days × Clear all
NCT07608224 2026-05-27

HOPE-07-MIBC

West China Hospital

Phase 2/3 Not yet recruiting
240 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
29 enrolled
Gastrointestinal

Rectal Neoplasms

NCT07507526 2026-04-02

DTP-HER2

Sun Yat-sen University

Phase 2 Not yet recruiting
76 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

West China Hospital

Not yet recruiting
30 enrolled
Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
146 enrolled
Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡